Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Kenvue Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $33.0B | |
|---|---|---|
| Revenue (ttm) | 15.4B | |
| Net income (ttm) | 1.7B | |
| EPS (ttm) | $0.85 | |
| Shares out | 1.9B | |
| P/E (trailing) | 22.7x | |
| P/E (forward) | 14.7x | |
| Dividend | $0.84 (4.34%) | |
| Volume | 6,839,244 | |
| Beta | 0.45 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-01-02 | 2023-01-01 | 2023-12-31 | 2024-12-29 | 2025-12-28 | Trend |
| Revenue | $15.05B | $14.95B | $15.44B | $15.46B | $15.12B | +0.1% |
| Gross profit | $8.42B | $8.29B | $8.64B | $8.96B | $8.79B | +1.1% |
| Operating income | $2.92B | $2.68B | $2.51B | $1.84B | $2.41B | -4.6% |
| Net income | $2.08B | $2.06B | $1.66B | $1.03B | $1.47B | -8.3% |
| EPS (diluted) | $1.21 | $1.20 | $0.90 | $0.54 | $0.76 | -11.0% |
| EBITDA | $3.66B | $3.28B | $3.18B | $2.47B | $2.94B | -5.3% |
| R&D | $355.0M | $375.0M | $399.0M | $408.0M | $382.0M | +1.8% |
| SG&A | $5.48B | $5.63B | $6.14B | $6.33B | $6.09B | +2.6% |
Recent company headlines from major financial publishers.
The base outcome assumes steady consumer replenishment in non-discretionary over-the-counter healthcare categories, maintaining predictable top-line progression and stable operating margins. Steady channel execution preserves shelf placement across mass retail partners while cash generation covers regular dividends and scheduled debt maturities. This modal path projects a target of $18.17 with an estimated probability of 55.0%, delivering an implied return of 5.6% against $17.20 (as of 2026-10-02).
In the bull outcome, brand reinvestment and strong clinical positioning accelerate organic revenue expansion across Self Care and international territories. Operating efficiencies expand operating margins toward peer benchmark levels, unlocking superior cash generation. At a target value of $23.53 carrying an estimated probability of 20.0%, this path offers an implied return of 36.8% relative to $17.20 (as of 2026-10-02).
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 6.2% | $20.0 | $20.7 | $21.4 | $22.2 | $23.1 |
| 6.7% | $18.5 | $19.0 | $19.6 | $20.3 | $21.0 |
| 7.2% | $17.3 | $17.7 | $18.2 | $18.7 | $19.3 |
| 7.7% | $16.2 | $16.6 | $16.9 | $17.4 | $17.8 |
| 8.2% | $15.3 | $15.6 | $15.9 | $16.2 | $16.6 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
